- Time of issue:2020-03-12 00:00:00
After years of research and development, we have a balanced and diversified product pipeline with a strategic focus on major cancers and other AR related diseases.
Note: 1.In addition, IND for basal-cell carcinoma indication has been cleared by FDA in the U.S.; 2. Will conduct phase II clinical trial directly due to good safety, and the protocol is under preparation
Scan the QR code to read on your phone
Product Pipeline R&D Platform
Copyright: Kintor Pharmaceutical Limited retains all copyrights. 苏ICP备19028699号-2 Powered by 300.cn
Complaints and Suggestions Tel: +86 512 62639935 Email: firstname.lastname@example.org